Cephalon/Chiron Myotrophin (IGF-1) shows 25% reduction in rate of ALS progression, company reports.
CEPHALON/CHIRON MYOTROPHIN 8-POINT ALS SCORE DIFFERENCE FROM PLACEBO after nine months of therapy is significant in a Phase III study, Cephalon Senior-VP Michael Murphy, MD/PhD, reported June 10 at the World Federation of Neurology Committee on Motor Neuron Diseases in Talloires, France. Amyotrophic lateral sclerosis patients receiving the highest dose of Myotrophin (somatomedin-C) had an average 18-point increase from baseline on the Appel ALS scale compared to a 26-point increase for placebo-treated patients. A 20-point change indicates a major functional change in the ability of Lou Gehrig's disease patients to care for themselves.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth